Exclusive: Valeant Pharmaceuticals International Inc (NYSE:VRX) Sentiment Worsened, Despite Downtrend

November 28, 2016 - By Winifred Garcia   ·   0 Comments

Exclusive: Valeant Pharmaceuticals International Inc (NYSE:VRX) Sentiment  Worsened,  Despite Downtrend

Sentiment for Valeant Pharmaceuticals International Inc (NYSE:VRX)

Valeant Pharmaceuticals International Inc (NYSE:VRX) institutional sentiment increased to 0.88 in Q2 2016. Its up 0.02, from 0.86 in 2016Q1. The ratio improved, as 159 investment professionals opened new or increased positions, while 185 sold and decreased positions in Valeant Pharmaceuticals International Inc. The investment professionals in our partner’s database now hold: 217.59 million shares, down from 268.27 million shares in 2016Q1. Also, the number of investment professionals holding Valeant Pharmaceuticals International Inc in their top 10 positions decreased from 23 to 16 for a decrease of 7. Sold All: 88 Reduced: 97 Increased: 107 New Position: 52.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $5.81 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.

About 31,340 shares traded hands. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 51.65% since April 25, 2016 and is downtrending. It has underperformed by 57.66% the S&P500.

Analysts await Valeant Pharmaceuticals Intl Inc (NYSE:VRX) to report earnings on March, 21. They expect $1.34 earnings per share, down 46.61% or $1.17 from last year’s $2.51 per share. VRX’s profit will be $453.96M for 3.20 P/E if the $1.34 EPS becomes a reality. After $1.55 actual earnings per share reported by Valeant Pharmaceuticals Intl Inc for the previous quarter, Wall Street now forecasts -13.55% negative EPS growth.

According to Zacks Investment Research, “Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.”

Accipiter Capital Management Llc holds 39.06% of its portfolio in Valeant Pharmaceuticals Intl Inc for 2.37 million shares. Claren Road Asset Management Llc owns 77,527 shares or 18.46% of their US portfolio. Moreover, Okumus Fund Management Ltd. has 14.79% invested in the company for 4.24 million shares. The New York-based Pershing Square Capital Management L.P. has invested 5.79% in the stock. North Tide Capital Llc, a Massachusetts-based fund reported 2.50 million shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 2 insider purchases, and 0 insider sales for $5.04 million net activity.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Ratings Coverage

Ratings analysis reveals 35% of Valeant Pharmaceuticals Intl’s analysts are positive. Out of 23 Wall Street analysts rating Valeant Pharmaceuticals Intl, 8 give it “Buy”, 3 “Sell” rating, while 12 recommend “Hold”. The lowest target is $11 while the high is $310. The stock’s average target of $104.42 is 508.86% above today’s ($17.15) share price. VRX was included in 80 notes of analysts from July 21, 2015. The firm earned “Buy” rating on Monday, April 11 by Rodman & Renshaw. Morgan Stanley downgraded Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Friday, October 2 to “Equal-Weight” rating. On Tuesday, November 3 the stock rating was maintained by RBC Capital Markets with “Outperform”. The stock has “Hold” rating given by Canaccord Genuity on Wednesday, March 2. Stifel Nicolaus maintained it with “Buy” rating and $65 target price in Wednesday, March 16 report. The firm has “Equal-Weight” rating given on Tuesday, November 17 by Morgan Stanley. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Buy” rating by Stifel Nicolaus on Wednesday, November 11. On Wednesday, October 14 the stock rating was maintained by Scotia Capital with “Sector Outperform”. The firm earned “Buy” rating on Wednesday, September 30 by Bank of America. As per Thursday, October 22, the company rating was downgraded by BMO Capital Markets.

VRX Company Profile

Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.

More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: Profitconfidential.com which released: “Valeant Pharmaceuticals Intl Inc: More Bad News for VRX Stock” on November 24, 2016, also Fool.com with their article: “Why Valeant Pharmaceuticals Intl Inc Stock Is Slumping Today” published on November 08, 2016, Fool.com published: “3 Figures in Focus When Valeant Pharmaceuticals Intl. Inc. Reports Its Q3 Results” on November 01, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were released by: Investorplace.com and their article: “Valeant Pharmaceuticals Intl Inc (VRX) Stock Owners Should Ask Tougher Questions” published on November 15, 2016 as well as Profitconfidential.com‘s news article titled: “Valeant Pharmaceuticals Intl Inc: VRX Stock Rises Again” with publication date: November 10, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Winifred Garcia

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>